Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M278,355Revenue $M74,331Net Margin (%)22.0Z-Score5.5
Enterprise Value $M260,617EPS $5.7Operating Margin %28.2F-Score7
P/E(ttm))16.7Cash Flow Per Share $6.2Pre-tax Margin (%)27.7Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %4.7Quick Ratio2.2Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-1.5Current Ratio2.6Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %23.6ROA % (ttm)14.8Higher Current Ratio y-yY
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)26.1Less Shares Outstanding y-yY
Payout Ratio %48.0Shares Outstanding M2,799ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJJohn Hussman 2014-12-31 Add1.19%$96.78 - $109.07
($105.37)
$ 100.11-5%Add 8301.89%111,325
JNJJoel Greenblatt 2014-12-31 Add0.66%$96.78 - $109.07
($105.43)
$ 100.11-5%Add 5420.84%790,529
JNJJohn Rogers 2014-12-31 Add0.11%$96.78 - $109.07
($105.37)
$ 100.11-5%Add 17.8%632,132
JNJHOTCHKIS & WILEY 2014-12-31 Sold Out $96.78 - $109.07
($105.37)
$ 100.11-5%Sold Out0
JNJRobert Olstein 2014-12-31 Reduce-0.17%$96.78 - $109.07
($105.37)
$ 100.11-5%Reduce -14.46%71,000
JNJRichard Perry 2014-12-31 Reduce-0.11%$96.78 - $109.07
($105.37)
$ 100.11-5%Reduce -8.67%312,610
JNJRay Dalio 2014-12-31 Reduce-0.02%$96.78 - $109.07
($105.37)
$ 100.11-5%Reduce -23.64%64,293
JNJRay Dalio 2014-09-30 Add0.02%$99.82 - $108.64
($103.64)
$ 100.11-3%Add 27.77%84,193
JNJJoel Greenblatt 2014-09-30 Buy 0.02%$99.82 - $108.64
($103.64)
$ 100.11-3%New holding, 14319 sh.14,319
JNJDodge & Cox 2014-09-30 Add$99.82 - $108.64
($103.64)
$ 100.11-3%Add 21.93%47,095
JNJHOTCHKIS & WILEY 2014-09-30 Reduce-0.53%$99.82 - $108.64
($103.64)
$ 100.11-3%Reduce -99.8%2,862
JNJJames Barrow 2014-09-30 Reduce-0.24%$99.82 - $108.64
($103.64)
$ 100.11-3%Reduce -10.05%15,350,650
JNJYacktman Focused Fund 2014-09-30 Reduce-0.21%$99.82 - $108.64
($103.64)
$ 100.11-3%Reduce -6.06%3,100,000
JNJDonald Yacktman 2014-09-30 Reduce-0.17%$99.82 - $108.64
($103.64)
$ 100.11-3%Reduce -4.36%8,651,258
JNJYacktman Fund 2014-09-30 Reduce-0.13%$99.82 - $108.64
($103.64)
$ 100.11-3%Reduce -3.7%3,900,000
JNJGeorge Soros 2014-09-30 Sold Out -0.04%$99.82 - $108.64
($103.64)
$ 100.11-3%Sold Out0
JNJJohn Rogers 2014-06-30 Add0.2%$96.54 - $105.76
($101.02)
$ 100.11-1%Add 42.46%522,727
JNJRichard Pzena 2014-06-30 Add0.17%$96.54 - $105.76
($101.02)
$ 100.11-1%Add 33.12%1,155,666
JNJHOTCHKIS & WILEY 2014-06-30 Reduce-0.89%$96.54 - $105.76
($101.02)
$ 100.11-1%Reduce -63.73%1,426,614
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 100.11-1%Reduce -13.16%3,300,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ John Hussman 2014-12-31111,32501.2+8301.89%
JNJ Joel Greenblatt 2014-12-31790,5290.030.67+5420.84%
JNJ John Rogers 2014-12-31632,1320.020.76+17.8%
JNJ James Barrow 2014-12-3115,491,3860.552.2+0.92%
JNJ Michael Price 2014-12-3135,00000.45
JNJ Tom Gayner 2014-12-31574,2000.021.6
JNJ Richard Snow 2014-12-313,27000.01
JNJ Prem Watsa 2014-12-3182,85000.56
JNJ Warren Buffett 2014-12-31327,1000.010.03
JNJ Brian Rogers 2014-12-314,633,0000.171.7
JNJ Yacktman Focused Fund 2014-12-313,100,0000.113.5
JNJ Yacktman Fund 2014-12-313,900,0000.143.5
JNJ Richard Pzena 2014-12-311,183,9660.040.66-0.04%
JNJ Ken Fisher 2014-12-3110,424,6070.372.3-0.21%
JNJ Ruane Cunniff 2014-12-3175,94600.04-0.41%
JNJ Donald Yacktman 2014-12-318,611,3590.313.7-0.46%
JNJ Tweedy Browne 2014-12-314,142,4450.1511.1-0.52%
JNJ PRIMECAP Management 2014-12-3112,143,4330.431.3-0.61%
JNJ Jean-Marie Eveillard 2014-12-311,616,9270.060.41-2.1%
JNJ Dodge & Cox 2014-12-3144,23500-6.07%
JNJ Mario Gabelli 2014-12-31336,9350.010.18-8.03%
JNJ Richard Perry 2014-12-31312,6100.011.4-8.67%
JNJ Robert Olstein 2014-12-3171,00000.91-14.46%
JNJ Ray Dalio 2014-12-3164,29300.05-23.64%
JNJ HOTCHKIS & WILEY 2014-12-31000Sold Out
JNJ Mark Hillman 2013-12-3130,74604.2-0.27%
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-7.78view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-6.81view
CULLEN JAMESDirector 2014-09-10Sell2,446$104.12-3.85view
Caruso Dominic JVP, Finance; CFO 2014-08-21Sell30,000$104.3-4.02view
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.050.06view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.157.47view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.399.54view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.686.86view
Stoffels PaulusChief Scientific Officer 2013-07-25Sell45,440$92.48.34view
Caruso Dominic JVP, Finance; CFO 2013-07-18Sell30,000$90.3110.85view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Berkshire Hathaway The All Season Stock Mar 03 2015 
    Dividend Growth Stocks Are My Conviction Mar 03 2015 
    Investing: Keep It Simple – Part 2 Feb 26 2015 
    A Look at SPY´s Value at Risk Feb 27 2015 
    Investing: Keep It Simple Feb 25 2015 
    All Investing Involves Risk Feb 24 2015 
    Johnson & Johnson Has A Potential Buyer For Its Medical Devices Unit Feb 24 2015 
    test Feb 23 2015 
    possible Feb 22 2015 

    More From Our Partners
    Pharmacyclics Set to Be Acquired by AbbVie for $21B - Analyst Blog Mar 6 2015 - ZACKS

    More From Other Websites
    Pharmacyclics Set to Be Acquired by AbbVie for $21B - Analyst Blog Mar 06 2015
    U.S. Equities, Oil And Gold Hammered After Upbeat Jobs Report Mar 06 2015
    US stocks plummet on Fed rate worries after jobs report Mar 06 2015
    Dividend-Hiking Companies Offer Extra Value With Direct Purchase Mar 06 2015
    Going the extra mile to win a £21bn deal Mar 06 2015
    Traders Look To Dividend Funds (VIG) Mar 06 2015
    Facebook, Apple among 379 that file to support gay marriage Mar 06 2015
    Biotech Bidding War Yields Rich Price Mar 06 2015
    Bristol-Myers gets faster than expected approval for first immuno oncology drug Mar 05 2015
    Billionaire Robert Duggan's Bet On Pharmacyclics Stands Among Top Trades Of Crisis Era Mar 05 2015
    Expect More M&A Activity In Red-Hot Biotech Group Mar 05 2015
    Leadership & the X factor Mar 05 2015
    This sector could be the best bet this year Mar 05 2015
    J&J Ordered to Pay $5.7 Million Over Incontinence Implant Mar 05 2015
    AbbVie Stock Slides On Pricey Pharmacyclics Deal Mar 05 2015
    Johnson & Johnson ordered to pay $5.7 mln in California mesh trial Mar 05 2015
    Johnson & Johnson ordered to pay $5.6 mln in California mesh trial Mar 05 2015
    AbbVie wins three-way fight over Pharmacyclics Mar 05 2015
    AbbVie boosts cancer drug pipeline with $21 bln Pharmacyclics deal Mar 05 2015
    AbbVie boosts cancer drug pipeline with $21 bln Pharmacyclics deal Mar 05 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Gurufocus
    ReplyGurufocus - 1 year ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK